SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Ovarian cancer classification system validated
Fri January 15th - A newly developed method for subtyping ovarian cancer has been validated as accurately predicting disease outcome. More
How euthanasia rates vary across The Netherlands
Fri January 15th - Regions of The Netherlands have recorded a seven-fold unexplained variation in euthanasia rates, according to new analysis published today. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Male contraceptive promise against cancer

Thursday December 29th, 2016

A drug developed as a male contraceptive may be able to treat testicular cancer, researchers have reported.

A German-Swiss study found that the drug JQ1 activates apoptosis in cancer cells.

So far the drug has been tested successfully in mouse models of the disease.

The researchers say it also shows promise as a combination drug.

The research has been undertaken at the University of Bonn, Germany, and at the University of St Gallen, Switzerland, together with researchers at Harvard Medical School, Massachusetts, USA.

JQ1 was designed to block sperm maturation and is able to inhibit certain genes.

The findings have been reported in the journals Journal of Cellular and Molecular Medicine and Oncotarget.

Researcher Sina Jostes said: "In a testicular cancer mouse model, the tumours began to shrink after administering JQ1.

"In contrast, healthy skin cells seem to tolerate JQ1 very well."

The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. Journal of Cellular and Molecular Medicine December 2016; doi: 10.1111/jcmm.13059

A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment; Oncotarget December 2016; doi: 10.18632/oncotarget.11647

Tags: Cancer | Men's Health | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES